Literature DB >> 20943204

miR-29a levels are elevated in the db/db mice liver and its overexpression leads to attenuation of insulin action on PEPCK gene expression in HepG2 cells.

Amit K Pandey1, Gaurav Verma, Saurabh Vig, Swayamprakash Srivastava, Arvind K Srivastava, Malabika Datta.   

Abstract

MicroRNAs comprise a class of small (∼22 nucleotide) non-coding RNA species and they bind to their complementary sequence on the 3'UTR of target genes and cause translational repression. In the present study, we report that miR-29a levels are significantly elevated in the diabetic db/db mice liver. Further, we report the effects of such elevation on insulin action in HepG2 cells. Overexpression of miR-29a narrowed down insulin mediated Akt phosphorylation without altering the total Akt levels presumably due to another upstream mediator being directly targeted by miR-29a. This hunt led us to the discovery that the p85α subunit of PI3K (phosphoionositide-3-kinase), the upstream molecule in the insulin signaling cascade harbors the miR-29a binding site on its 3'UTR and a marked inhibition of PI3Kp85α was observed by this microRNA. This was consequently accompanied by attenuation of insulin inhibition of PEPCK gene expression. All these events could be significantly prevented in the presence of the miR-29a inhibitor. Our results, for the first time, show the effect of miR-29a in counteracting insulin action on PEPCK gene expression by primarily targeting PI3K and abrogating downstream insulin signaling in HepG2 cells.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20943204     DOI: 10.1016/j.mce.2010.10.004

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  48 in total

Review 1.  Minireview: microRNA function in pancreatic β cells.

Authors:  Sabire Ozcan
Journal:  Mol Endocrinol       Date:  2014-12

2.  Developmental programming: gestational testosterone treatment alters fetal ovarian gene expression.

Authors:  Lacey J Luense; Almudena Veiga-Lopez; Vasantha Padmanabhan; Lane K Christenson
Journal:  Endocrinology       Date:  2011-10-18       Impact factor: 4.736

Review 3.  Role of miRNAs in the pathogenesis and susceptibility of diabetes mellitus.

Authors:  Naoko Hashimoto; Tomoaki Tanaka
Journal:  J Hum Genet       Date:  2016-12-08       Impact factor: 3.172

4.  Downregulation of miR-181a upregulates sirtuin-1 (SIRT1) and improves hepatic insulin sensitivity.

Authors:  B Zhou; C Li; W Qi; Y Zhang; F Zhang; J X Wu; Y N Hu; D M Wu; Y Liu; T T Yan; Q Jing; M F Liu; Q W Zhai
Journal:  Diabetologia       Date:  2012-04-04       Impact factor: 10.122

Review 5.  MicroRNAs in metabolism and metabolic disorders.

Authors:  Veerle Rottiers; Anders M Näär
Journal:  Nat Rev Mol Cell Biol       Date:  2012-03-22       Impact factor: 94.444

Review 6.  The two faces of miR-29.

Authors:  Anna Ślusarz; Lakshmi Pulakat
Journal:  J Cardiovasc Med (Hagerstown)       Date:  2015-07       Impact factor: 2.160

Review 7.  Beyond the Protein-Coding Sequence: Noncoding RNAs in the Pathogenesis of Type 2 Diabetes.

Authors:  Johanna K DiStefano
Journal:  Rev Diabet Stud       Date:  2016-01-28

8.  Histone deacetylase inhibition regulates miR-449a levels in skeletal muscle cells.

Authors:  Shagun Poddar; Devesh Kesharwani; Malabika Datta
Journal:  Epigenetics       Date:  2016-05-16       Impact factor: 4.528

Review 9.  MicroRNAs in the onset and development of cardiovascular disease.

Authors:  Kasey C Vickers; Kerry-Anne Rye; Fatiha Tabet
Journal:  Clin Sci (Lond)       Date:  2014-02       Impact factor: 6.124

10.  MicroRNA-29 family inhibits rhabdomyosarcoma formation and progression by regulating GEFT function.

Authors:  Yang Wang; Liang Zhang; Yuweng Pang; Lingxie Song; Hao Shang; Zhenzhen Li; Qianqian Liu; Yangyang Zhang; Xiaomeng Wang; Qianru Li; Qiaochu Zhang; Chunxia Liu; Feng Li
Journal:  Am J Transl Res       Date:  2020-03-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.